SHARE YOUR STORY
In 2017, 80,000 people were denied a PCSK9 inhibitor by health plans.
For some, these advanced cardiovascular therapies are a last resort to prevent a debilitating heart attack or stroke.
If you’ve been denied access to a PCSK9 inhibitor, let us know below. We’re looking for advocates who are willing to speak up.